Hussain Izhar M, Naqvi Baqir S, Qasim Rao M, Ali Nasir
Izhar M. Hussain, M. Pharm., MBA. Director, Center for Executive Education, Institute of Business Administration, IBA City Campus, Garden / Kiyani Shaheed Road, Karachi, Pakistan.
Dr. Baqir S. Naqvi, PhD. Professor, Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, Karachi, Pakistan.
Pak J Med Sci. 2015 Sep-Oct;31(5):1021-6. doi: 10.12669/pjms.315.7438.
This study finds out drug usage trends in Stage I Hypertensive Patients without any compelling indications in Karachi, deviations of current practices from evidence based antihypertensive therapeutic guidelines and looks for cost minimization opportunities.
In the present study conducted during June 2012 to August 2012, two sets were used. Randomized stratified independent surveys were conducted in doctors and general population - including patients, using pretested questionnaires. Sample sizes for doctors and general population were 100 and 400 respectively. Statistical analysis was conducted on Statistical Package for Social Science (SPSS). Financial impact was also analyzed.
On the basis of patients' doctors' feedback, Beta Blockers, and Angiotensin Converting Enzyme Inhibitors were used more frequently than other drugs. Thiazides and low-priced generics were hardly prescribed. Beta blockers were prescribed widely and considered cost effective. This trend increases cost by two to ten times.
Feedbacks showed that therapeutic guidelines were not followed by the doctors practicing in the community and hospitals in Karachi. Thiazide diuretics were hardly used. Beta blockers were widely prescribed. High priced market leaders or expensive branded generics were commonly prescribed. Therefore, there are great opportunities for cost minimization by using evidence-based clinically effective and safe medicines.
本研究旨在查明卡拉奇地区无任何强制适应症的I期高血压患者的用药趋势、当前治疗方法与循证抗高血压治疗指南的偏差,并寻找成本最小化的机会。
在2012年6月至2012年8月进行的本研究中,使用了两组样本。采用预先测试的问卷,对医生和普通人群(包括患者)进行随机分层独立调查。医生和普通人群的样本量分别为100和400。使用社会科学统计软件包(SPSS)进行统计分析,并分析了财务影响。
根据患者及其医生的反馈,β受体阻滞剂和血管紧张素转换酶抑制剂的使用频率高于其他药物。噻嗪类药物和低价仿制药很少被处方。β受体阻滞剂被广泛处方且被认为具有成本效益。这种趋势使成本增加了两到十倍。
反馈表明,在卡拉奇社区和医院执业的医生未遵循治疗指南。噻嗪类利尿剂很少使用。β受体阻滞剂被广泛处方。高价的市场领先药物或昂贵的品牌仿制药通常被处方。因此,通过使用循证的临床有效且安全的药物,有很大的成本最小化机会。